A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …
features, with α-synuclein pathology as the gold standard to establish the definitive …
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …
disease modifying treatment for any of the most common types of dementia such as …
Structural mechanism for specific binding of chemical compounds to amyloid fibrils
Y Tao, W **a, Q Zhao, H **ang, C Han, S Zhang… - Nature Chemical …, 2023 - nature.com
Amyloid fibril is an important pharmaceutical target for diagnostic and therapeutic treatment
of neurodegenerative diseases. However, rational design of chemical compounds that …
of neurodegenerative diseases. However, rational design of chemical compounds that …
Single-domain antibody–based noninvasive in vivo imaging of α-synuclein or tau pathology
Intracellular deposition of α-synuclein and tau are hallmarks of synucleinopathies and
tauopathies, respectively. Recently, several dye-based imaging probes with selectivity for …
tauopathies, respectively. Recently, several dye-based imaging probes with selectivity for …
Morphological basis of Parkinson disease-associated cognitive impairment: an update
KA Jellinger - Journal of Neural Transmission, 2022 - Springer
Cognitive impairment is one of the most salient non-motor symptoms of Parkinson disease
(PD) that poses a significant burden on the patients and carers as well as being a risk factor …
(PD) that poses a significant burden on the patients and carers as well as being a risk factor …
How should we be using biomarkers in trials of disease modification in Parkinson's disease?
The recent validation of the α-synuclein seed amplification assay as a biomarker with high
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …
The role of exosomes in the diagnosis of Parkinson's disease
Q Shi, W Kang, Z Liu, X Zhu - Heliyon, 2023 - cell.com
Parkinson's disease is a common neurodegenerative disease characterized by intracellular
aggregation of misfolded α-synuclein as a major pathological hallmark. Exosomes are cell …
aggregation of misfolded α-synuclein as a major pathological hallmark. Exosomes are cell …
Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta‐analysis
Introduction Operationalized research criteria for mild cognitive impairment with Lewy
bodies (MCI‐LB) were published in 2020. The aim of this systematic review and meta …
bodies (MCI‐LB) were published in 2020. The aim of this systematic review and meta …
A Novel Brain PET Radiotracer for Imaging Alpha Synuclein Fibrils in Multiple System Atrophy
Abnormal α-synuclein (α-syn) aggregation characterizes α-synucleinopathies, including
Parkinson's disease (PD) and multiple system atrophy (MSA). However, no suitable positron …
Parkinson's disease (PD) and multiple system atrophy (MSA). However, no suitable positron …
Toward a biological definition of neuronal and glial synucleinopathies
Cerebral accumulation of alpha-synuclein (αSyn) aggregates is the hallmark event in a
group of neurodegenerative diseases—collectively called synucleinopathies—which …
group of neurodegenerative diseases—collectively called synucleinopathies—which …